Abstract

Certolizumab Pegol as a Treatment Option for Early Rheumatoid Arthritis Patients After Disease-Modifying Antirheumatic Drug Failure

Author(s): Simone Appenzeller*

Certolizumab Pegol, a pegylated anti-TNF (tumor necrosis factor) biologic, has become an important therapeutic option for patients with rheumatoid arthritis (RA) who experience insufficient responses to traditional disease-modifying antirheumatic drugs (DMARDs). In early RA, where aggressive disease progression can lead to permanent joint damage, timely and effective treatment is crucial. Certolizumab Pegol targets TNF-alpha, a key inflammatory cytokine driving RA pathogenesis, offering significant benefits in controlling inflammation, reducing disease activity, and preventing joint destruction. This review examines the clinical efficacy, safety profile, and role of Certolizumab Pegol in patients with early RA who have failed conventional DMARDs. The paper also explores its integration into treatment plans, potential combination therapies, and its impact on improving long-term patient outcomes in early disease stages.